Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally to Prevent the Recurrence of Bacterial Vaginosis

NCT01437722 is registered in ClinicalTrials.gov with Starpharma Pty Ltd as lead sponsor.

NCT NCT01437722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01437722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally to Prevent the Recurrence of Bacterial Vaginosis
Lead sponsor
Starpharma Pty Ltd
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
Not reported
Enrollment
205 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent bacterial vaginosis (bv)